Evonik Releases Financial Results Statement and Expects No Recovery in Global Chemical Market Demand in 2026

What is most worth savoring in Evonik’s latest update is not that it kept its 2026 adjusted EBITDA guidance unchanged at between €1.7 billion and €2.0 billion, but that in doing so, it almost laid bare the harshest truth the entire chemical industry is currently unwilling to face: the market has not clearly recovered, demand has not truly returned, and the industry’s better days are, at the very least, not here yet. According to data disclosed in Evonik’s latest annual report, the group recorded sales of €14.069 billion in 2025 and adjusted EBITDA of €1.874 billion, landing squarely within the profit guidance range it has now set for 2026. The company’s core judgment for 2026 is equally clear: the environment of “low growth, weak demand, and intertwined geopolitical and economic uncertainty” that defined the past year will largely continue into 2026.

That may not sound dramatic, but it cuts more sharply than many so-called “cautious outlooks.” Because for a global specialty chemicals leader, maintaining a profit range is not in itself particularly unusual. What truly stands out is that Evonik did not use its annual report to package some upbeat story about “things getting better in the second half” or “an inflection point in demand already appearing.” On the contrary, the company stated it quite plainly in the report: the persistent weakness in key end markets will largely continue in 2026, and global industrial output is expected to grow even more slowly than in 2025, which was already hardly a strong year. This is not ordinary conservative wording, but a very typical market-leading posture: not trying to flatter sentiment, but first placing reality on the table. In other words, what Evonik is trying to prove to investors now is not “the industry is about to rebound,” but rather “even if the industry does not rebound, I can still defend profitability.”

Behind that sits a very important dividing line for the industry. In the past, many chemical companies still managed expectations by placing at least some hope in a natural recovery of demand, as if macro conditions only needed to loosen a little, inventories to decline a bit, orders to recover somewhat, and then earnings would be able to rise rather smoothly. But the signal Evonik is sending this time is almost the exact opposite: today’s chemical companies, especially European chemical companies, can increasingly no longer rely on the market “getting better by itself” to repair profits. They have to place much more of the burden on structural optimization, cost control, and portfolio management. From the company’s own disclosures, the reason earnings are expected to remain stable in 2026 is not because demand will suddenly take off, but because of cost discipline, the Evonik Tailor Made restructuring program, optimization projects across business segments, and the continued savings generated by short-term measures. Together with somewhat more moderate energy prices than in 2025 and some tailwind from German government support programs, these factors form its profitability defense line.

Put even more plainly, Evonik is not fighting an offensive war right now, but a textbook defensive counterattack. It knows perfectly well that the global chemicals market is not currently an environment in which “whoever expands most aggressively wins first.” It is much more like an environment in which “whoever stabilizes the base first, eliminates inefficient links first, and makes its assets and businesses more shock-resistant will live more comfortably.” Europe in particular is a case in point. Evonik is very explicit in its outlook: weak European manufacturing, energy costs that remain above international levels, regulatory pressure, and the external impact of U.S. protectionist trade policy will all continue to weigh on regional momentum. In other words, what European chemical companies are facing today is no longer a simple cyclical downturn, but a compound pressure of cost disadvantage, weak demand, and policy uncertainty all layered together. That is also why so many European chemical companies today do not look terrible, but neither does anyone dare say lightly that they have already returned to a stage of high growth.

What makes Evonik special is that it is not, in the traditional sense, a bulk chemicals heavy-asset player, but a classic specialty chemicals leader. In theory, specialty chemicals should have stronger customer stickiness, better pricing power, and a more defensive product structure than basic chemicals, making them less likely to be overturned by cyclical volatility. That is precisely why Evonik, even while admitting demand will not visibly recover, can still maintain 2026 adjusted EBITDA guidance at €1.7 billion to €2.0 billion. But that does not mean specialty chemicals can fully detach themselves from the broader environment. The report is equally clear that most Advanced Technologies businesses will still face persistently weak market demand in 2026, and that some businesses will continue to operate under intense competitive pressure. Even product lines such as Crosslinkers will still feel obvious competitive compression. This shows that the moat around specialty chemicals still exists today, but it is no longer wide enough to block out all macro headwinds.

That is precisely why the most important thing in Evonik’s outlook is not that “earnings are stable,” but that they are stable under highly specific conditions. This is not the kind of stability that says, “demand is weak but the company is naturally strong, so earnings are safe.” It is the kind that says, “demand is weak, competition is intense, and the macro environment is poor, so I have to become more precise than before in how I run the business.” The difference in temperament is enormous. The former is a kind of relaxed superiority; the latter is a highly industrialized form of self-discipline. You begin to see that the chemical leaders still capable of defending earnings guidance are increasingly the ones best at subtraction, best at calculating marginal returns, and least addicted to the illusion of scale. When the tide is not rising, it becomes very easy to tell who is still swimming naked, and who has already changed to the most economical, durable stroke.

If we shift the lens toward China and Asia-Pacific, the whole thing becomes even more interesting. Evonik has not weakened its focus on Asia-Pacific because of short-term pressure. On the contrary, it continues in public materials to emphasize the importance of Asia, especially China. The annual report shows that Asia-Pacific accounted for 23% of group sales in 2025, contributing €3.213 billion. The company is also continuing the expansion of its specialty amines facility in Nanjing, China. Those products are used in epoxy and polyurethane foam applications, among others, and the project is planned for completion in 2026 in order to improve market efficiency. At the same time, Evonik’s China website states that the group recorded global sales of €14.1 billion in 2025 and adjusted EBITDA of around €1.9 billion; public reporting has also shown that Evonik’s China sales reached around €1.4 billion in 2024, roughly 10% of global business, while company management in China has explicitly expressed confidence in the country’s long-term growth prospects. Taken together, this says a great deal: Evonik has not abandoned China, nor does it regard China as some optional regional market. It still sees China as a highly important piece of its future growth structure.

Yet the more that is true, the more meaningful Evonik’s present tone becomes. Because this is not a company with no stake in China and no expectations for Asia-Pacific. On the contrary, it has long-term investment, production expansion, and R&D commitments in China, and it fully understands China’s significance in the global chemicals growth map. Even so, it still offers very little easy optimism about 2026. That shows the problem is not that the company lacks confidence in China, but that short-term demand recovery across the whole industry truly has not improved enough to change the tone even of a leading company. From the report, Evonik’s judgment on Asia is also qualified: Asia will still grow, but growth will remain weak; China will remain important, but China no longer automatically means “high-elasticity incremental growth right away”; and global trade frictions and geopolitical risks may continue to affect China and other major trading partners. That judgment feels far more real than a simple “long-term bullish on China” slogan. It sounds much more like what a company truly operating on a global scale would say.

So what the industry should really linger over here is not that Evonik is “pessimistic,” but that it has accepted a new normal earlier than many others: for some time to come, the chemical industry will probably neither collapse across the board, nor recover in any smooth or satisfying way. It looks more like an extended, blunt pain. Demand is weak, but not frozen. Prices fluctuate, but not in a one-way loss of control. Some segments are growing, but not enough to lift overall industry mood. For companies, this kind of environment can be even more troublesome than a boom-bust cycle. In extreme markets, firms at least find it easier to move in unison. In a lukewarm environment where isolated bright spots coexist with broad stagnation, management makes its biggest mistakes when it confuses local improvement with full recovery, or structural highlights with a complete cyclical turnaround. What is admirable about Evonik this time is precisely that it has not made that mistake.

From both an investment and industrial perspective, Evonik’s outlook is also redefining what a “good company” really means. In the past, people liked to talk about chemical leaders in terms of how fast they were expanding, how hot their sectors were, or how fashionable their themes sounded. But in the reality of 2026, the standard with real weight may be quite different: can a company hold margins when demand does not recover, stabilize cash flow when prices are unfriendly, and allocate resources more intelligently when regional momentum diverges? If the last round of industry competition was about the courage to expand, this round looks much more like a contest of operating endurance. Evonik is not the only company doing this, but it is saying it more clearly than most, which is why it is especially worth taking as a sample.

Look deeper still, and there is another easily overlooked signal in Evonik’s decision to keep its earnings guidance unchanged: the way chemical leaders now think about “quality of earnings” has changed markedly from the past. The report repeatedly mentions not simply pursuing volume, but emphasizing high utilization, structural growth, innovation growth fields, focused management, and optimization of cost position. On the surface, these may sound like standard annual report management language. But placed in today’s industry context, they all point toward the same thing: companies have already accepted that future growth will no longer naturally rise on the back of an industry-wide tailwind, but will depend much more heavily on a small number of high-quality businesses, a small number of high-momentum niches, and much more precise operational control. In other words, Evonik is maintaining guidance not because “its plate is big enough,” but because it is trying to make the profitable parts of its business matter more.

That has obvious implications for the entire chemicals sector. Many companies today are also talking about structural optimization, cost discipline, and regional balance, but very few are truly translating those things into the income statement. Many are still waiting for the market to recover, waiting for customers to return, waiting for orders to improve on their own. Evonik’s logic, by contrast, is clearly this: a market recovery would of course be welcome, but before that recovery arrives, a company has to learn to remake itself into a system capable of surviving a low-cycle period with a leaner organization, more precise capital spending, and a more focused portfolio. That is the real penetrating force of this results statement. It may look as though the company is merely maintaining guidance, but in reality it is telling the whole industry something much bigger: stop placing all your hope on external recovery, and start making yourselves into businesses capable of crossing a prolonged low-demand cycle.

At the end of the day, the coolest and most seasoned thing about Evonik this time is that it is not selling hope, but selling certainty. While the whole industry is still asking when the recovery will come, Evonik has already worked out the answer to the question of what to do if it does not. That is closer than any beautiful slogan to the truth of today’s chemical world. For customers, it means suppliers will place more emphasis on profit discipline and business quality. For peers, it means competition is no longer only about grabbing volume, but about who can endure longer and calculate more precisely. For the market, it means the company truly worth regarding more highly may not be the loudest one, but the one that has already managed itself into stability before the industry has warmed up again.